Advertisement


Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

2024 ASCO Annual Meeting

Advertisement

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We designed the study back in 2012. It was a study of metformin, men with active surveillance for prostate cancer, and there was a lot of rationales as to why metformin would be useful in prostate cancer. There's laboratory studies that we've done speaking to the importance of metformin inhibiting mTOR as well as having epigenetic effects. There's data from other groups looking at the beneficial effect of metformin on the tumor microenvironment. There's epidemiological studies that suggest that diabetic men who take metformin do better for their prostate cancer treatment. There's combination studies that we've done demonstrating that, in some of the pivotal prostate cancer studies, the men who took metformin did better in the studies with abiraterone. So we put all those things together. We thought, well, metformin may be the perfect medication to give men undergoing active surveillance of prostate cancer. So from the period of 2013 to 2023, we randomised 400 men, approximately 204 on each arm to take metformin versus a matched placebo when they were undergoing active surveillance. And active surveillance is briefly, as per NCCN, very low to low risk criteria. Basically men with low volume Gleason 6 disease, and there's more details in the presentation, but those men were randomised over that period, and the endpoint was defined as either being therapeutic progression or pathological progression. The pathological progression was biopsies done at 18 and 36 months, and their therapeutic progression was any treatment for prostate cancer. And in brief, we found no difference between the arms, and in fact, there was a couple of concerning trends. One trend was that men who had a high BMI actually seemed to do worse on metformin for reasons we don't understand. And a priori, you would think those men would do better on metformin because they may lose weight, but that was not the case. And also there seemed to be a slight trend towards men progressing with higher Gleason scores who took metformin compared to those men who took placebo. This is a little bit worrying, and certainly we need to do more research to understand why this is the case. But this study was an academic study across 12 centers in Canada, funded through, essentially philanthropy, the Prostate Cancer Foundation, and the Canadian Cancer Association. So taken together, I think this has been a great academic effort. It will seed a lot of future research to understand the role of metformin and those types of drugs in men with and without diabetes for prostate cancer undergoing active surveillance.

Related Videos

Breast Cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Breast Cancer

Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options

Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may help clinicians identify those patients with a favorable prognosis for adjuvant endocrine therapy and those who may require additional treatment (Abstract 560).

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Advertisement

Advertisement




Advertisement